FT. LAUDERDALE, Fla.--(EON: Enhanced Online News)--Puget Technologies (OTCBB: PUGE) announced today its Cannabis BioTech subsidiary has executed a consulting agreement with Kenneth Morrow, a leading international medical marijuana consultant, to round out the company’s research and development team.
“On par with the world’s best, Ken’s vast experience with cannabis projects across the globe will be a tremendous asset to Cannabis BioTech.”
The California based Morrow is a prominent international cannabis authority with more than 30 years’ experience. A globally recognized expert on production and delivery techniques and practices, Morrow serves as a consultant for some of the world’s largest companies involved in the advancement of medical marijuana. He has appeared on both CNN and 60 Minutes to discuss industry developments.
Morrow is the founder and owner of Trichome Technologies, which is involved in pioneering and evolving the cannabinoid industry and researching terpenes in marijuana. Terpenes are aromatic plant compounds found to have numerous health benefits.
President and CEO of Puget Technologies Ron Leyland said, “We welcome Ken to our team and look forward to making great strides in our goal of developing and producing superior delivery options for patients who cannot or do not desire to smoke marijuana.” He added, “On par with the world’s best, Ken’s vast experience with cannabis projects across the globe will be a tremendous asset to Cannabis BioTech.”
Amid changing attitudes about marijuana, Cannabis Biotech is dedicated to developing medicinal cannabinoid delivery options using scientific research and methodologies. The investigations conducted at Cannabis BioTech are expected to add to the growing body of data demonstrating marijuana’s medicinal benefits.
According to a recent Pew Research report, for the first time in more than 40 years a majority of Americans favor legalization of marijuana use. Numerous countries, 20 U.S. states and the District of Columbia have legalized the use of medical marijuana.
Morrow said, “As new generations of freer-thinking voters replace the declining population of baby boomers, we are about to experience a huge shift in attitudes about the value of medical marijuana. Firsthand knowledge will demonstrate medical cannabinoid products are safer and more effective than many synthetic, toxic medications currently in use.”
More information about Cannabis BioTech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.